Eli Merle's questions to Arvinas Inc (ARVN) leadership • Q2 2025
Question
Tejas, on behalf of Eli Merle, asked for more details on the preclinical data for the KRAS program expected later in the year and how that might inform expectations for the Phase 1 trial of ARV-806.
Answer
CSO Angela Cacace detailed that upcoming preclinical data will highlight ARV-806's differentiation from inhibitors, its combinability with EGFR-targeted agents, and its ability to overcome resistance mechanisms. She also mentioned compelling data from the oral pan-KRAS program will be shared, including its potential for better combinability with immuno-oncology agents compared to pan-RAF inhibitors. This strong preclinical profile is driving investigator interest in the ongoing clinical trial.